In a much awaited clinical study in RA research, the previously mentioned EPC liposomes incorporating the NF-κB inhibitor BAY11-7082 and citrullinated peptides are injected in RA patients for antigen-specific inhibition of pro-arthritic immune responses (142). The gene discussed is NFKB1; the disease is rheumatoid arthritis.